Preclinical efficacy testing in middle-aged rats: Nicotinamide, a novel neuroprotectant, demonstrates diminished preclinical efficacy after controlled cortical impact

Alicia A. Swan, Rupa Chandrashekar, Jason Beare, Michael R. Hoane

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Age is a consistent predictor of poor outcome following traumatic brain injury (TBI). Although the elderly population has one of the highest rates of TBI-related hospitalization and death, few preclinical studies have attempted to model and treat TBI in the aged population. Recent studies have indicated that nicotinamide (NAM), a soluble B-group vitamin, improved functional recovery in experimental models of TBI in young animals. The purpose of the present study was to examine the preclinical efficacy of NAM in middle-aged rats. Groups of middle-aged (14-month-old) rats were assigned to NAM (500 mg/kg or 50 mg/kg) or saline alone (1 mL/kg) treatment conditions, and received unilateral cortical contusion injuries (CCI) and injections at 1 h and 24 h following injury. The animals were tested on a variety of tasks to assess vestibulomotor (tapered beam) and cognitive performance (reference and working memory in the Morris water maze), and were evaluated for lesion size, blood-brain barrier compromise, astrocytic activation, and edema formation. In summary, the preclinical efficacy of NAM as a treatment following CCI in middle-aged rats differs from that previously documented in younger rats; while treatment with 50 mg/kg NAM appeared to have no effect, the 500-mg/kg dose worsened performance in middle-aged animals. Histological indicators demonstrated more nuanced group differences, indicating that NAM may positively impact some of the cellular cascades following injury, but were not substantial enough to improve functional recovery. These findings emphasize the need to examine potential treatments for TBI utilizing non-standard populations, and may explain why so many treatments have failed in clinical trials.

Original languageEnglish (US)
Pages (from-to)431-440
Number of pages10
JournalJournal of Neurotrauma
Volume28
Issue number3
DOIs
StatePublished - Mar 1 2011

Fingerprint

Niacinamide
Neuroprotective Agents
Wounds and Injuries
Population
Therapeutics
Vitamin B Complex
Blood-Brain Barrier
Short-Term Memory
Edema
Hospitalization
Theoretical Models
Traumatic Brain Injury
Clinical Trials
Injections
Water

Keywords

  • CCI
  • aging
  • nicotinamide
  • recovery of function
  • therapy
  • traumatic brain injury

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Preclinical efficacy testing in middle-aged rats : Nicotinamide, a novel neuroprotectant, demonstrates diminished preclinical efficacy after controlled cortical impact. / Swan, Alicia A.; Chandrashekar, Rupa; Beare, Jason; Hoane, Michael R.

In: Journal of Neurotrauma, Vol. 28, No. 3, 01.03.2011, p. 431-440.

Research output: Contribution to journalArticle

@article{0474f548ab534b9b8c6b9a5adc077497,
title = "Preclinical efficacy testing in middle-aged rats: Nicotinamide, a novel neuroprotectant, demonstrates diminished preclinical efficacy after controlled cortical impact",
abstract = "Age is a consistent predictor of poor outcome following traumatic brain injury (TBI). Although the elderly population has one of the highest rates of TBI-related hospitalization and death, few preclinical studies have attempted to model and treat TBI in the aged population. Recent studies have indicated that nicotinamide (NAM), a soluble B-group vitamin, improved functional recovery in experimental models of TBI in young animals. The purpose of the present study was to examine the preclinical efficacy of NAM in middle-aged rats. Groups of middle-aged (14-month-old) rats were assigned to NAM (500 mg/kg or 50 mg/kg) or saline alone (1 mL/kg) treatment conditions, and received unilateral cortical contusion injuries (CCI) and injections at 1 h and 24 h following injury. The animals were tested on a variety of tasks to assess vestibulomotor (tapered beam) and cognitive performance (reference and working memory in the Morris water maze), and were evaluated for lesion size, blood-brain barrier compromise, astrocytic activation, and edema formation. In summary, the preclinical efficacy of NAM as a treatment following CCI in middle-aged rats differs from that previously documented in younger rats; while treatment with 50 mg/kg NAM appeared to have no effect, the 500-mg/kg dose worsened performance in middle-aged animals. Histological indicators demonstrated more nuanced group differences, indicating that NAM may positively impact some of the cellular cascades following injury, but were not substantial enough to improve functional recovery. These findings emphasize the need to examine potential treatments for TBI utilizing non-standard populations, and may explain why so many treatments have failed in clinical trials.",
keywords = "CCI, aging, nicotinamide, recovery of function, therapy, traumatic brain injury",
author = "Swan, {Alicia A.} and Rupa Chandrashekar and Jason Beare and Hoane, {Michael R.}",
year = "2011",
month = "3",
day = "1",
doi = "10.1089/neu.2010.1519",
language = "English (US)",
volume = "28",
pages = "431--440",
journal = "Journal of Neurotrauma",
issn = "0897-7151",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Preclinical efficacy testing in middle-aged rats

T2 - Nicotinamide, a novel neuroprotectant, demonstrates diminished preclinical efficacy after controlled cortical impact

AU - Swan, Alicia A.

AU - Chandrashekar, Rupa

AU - Beare, Jason

AU - Hoane, Michael R.

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Age is a consistent predictor of poor outcome following traumatic brain injury (TBI). Although the elderly population has one of the highest rates of TBI-related hospitalization and death, few preclinical studies have attempted to model and treat TBI in the aged population. Recent studies have indicated that nicotinamide (NAM), a soluble B-group vitamin, improved functional recovery in experimental models of TBI in young animals. The purpose of the present study was to examine the preclinical efficacy of NAM in middle-aged rats. Groups of middle-aged (14-month-old) rats were assigned to NAM (500 mg/kg or 50 mg/kg) or saline alone (1 mL/kg) treatment conditions, and received unilateral cortical contusion injuries (CCI) and injections at 1 h and 24 h following injury. The animals were tested on a variety of tasks to assess vestibulomotor (tapered beam) and cognitive performance (reference and working memory in the Morris water maze), and were evaluated for lesion size, blood-brain barrier compromise, astrocytic activation, and edema formation. In summary, the preclinical efficacy of NAM as a treatment following CCI in middle-aged rats differs from that previously documented in younger rats; while treatment with 50 mg/kg NAM appeared to have no effect, the 500-mg/kg dose worsened performance in middle-aged animals. Histological indicators demonstrated more nuanced group differences, indicating that NAM may positively impact some of the cellular cascades following injury, but were not substantial enough to improve functional recovery. These findings emphasize the need to examine potential treatments for TBI utilizing non-standard populations, and may explain why so many treatments have failed in clinical trials.

AB - Age is a consistent predictor of poor outcome following traumatic brain injury (TBI). Although the elderly population has one of the highest rates of TBI-related hospitalization and death, few preclinical studies have attempted to model and treat TBI in the aged population. Recent studies have indicated that nicotinamide (NAM), a soluble B-group vitamin, improved functional recovery in experimental models of TBI in young animals. The purpose of the present study was to examine the preclinical efficacy of NAM in middle-aged rats. Groups of middle-aged (14-month-old) rats were assigned to NAM (500 mg/kg or 50 mg/kg) or saline alone (1 mL/kg) treatment conditions, and received unilateral cortical contusion injuries (CCI) and injections at 1 h and 24 h following injury. The animals were tested on a variety of tasks to assess vestibulomotor (tapered beam) and cognitive performance (reference and working memory in the Morris water maze), and were evaluated for lesion size, blood-brain barrier compromise, astrocytic activation, and edema formation. In summary, the preclinical efficacy of NAM as a treatment following CCI in middle-aged rats differs from that previously documented in younger rats; while treatment with 50 mg/kg NAM appeared to have no effect, the 500-mg/kg dose worsened performance in middle-aged animals. Histological indicators demonstrated more nuanced group differences, indicating that NAM may positively impact some of the cellular cascades following injury, but were not substantial enough to improve functional recovery. These findings emphasize the need to examine potential treatments for TBI utilizing non-standard populations, and may explain why so many treatments have failed in clinical trials.

KW - CCI

KW - aging

KW - nicotinamide

KW - recovery of function

KW - therapy

KW - traumatic brain injury

UR - http://www.scopus.com/inward/record.url?scp=79952774476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952774476&partnerID=8YFLogxK

U2 - 10.1089/neu.2010.1519

DO - 10.1089/neu.2010.1519

M3 - Article

C2 - 21083416

AN - SCOPUS:79952774476

VL - 28

SP - 431

EP - 440

JO - Journal of Neurotrauma

JF - Journal of Neurotrauma

SN - 0897-7151

IS - 3

ER -